Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2008

Open Access 01-12-2008 | Research

Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines

Authors: Faisal M Fadlelmola, Minglong Zhou, Ronald J de Leeuw, Nirpjit S Dosanjh, Karynn Harmer, David Huntsman, Wan L Lam, Diponkar Banerjee

Published in: Molecular Cancer | Issue 1/2008

Login to get access

Abstract

Background

Hodgkin lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL), are forms of malignant lymphoma defined by unique morphologic, immunophenotypic, genotypic, and clinical characteristics, but both overexpress CD30. We used sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization to screen HL-derived cell lines (KMH2 and L428) and ALCL cell lines (DEL and SR-786) in order to identify disease-associated gene copy number gains and losses.

Results

Significant copy number gains and losses were observed on several chromosomes in all four cell lines. Assessment of copy number alterations with 26,819 DNA segments identified an average of 20 genetic alterations. Of the recurrent minimally altered regions identified, 11 (55%) were within previously published regions of chromosomal alterations in HL and ALCL cell lines while 9 (45%) were novel alterations not previously reported. HL cell lines L428 and KMH2 shared gains in chromosome cytobands 2q23.1-q24.2, 7q32.2-q36.3, 9p21.3-p13.3, 12q13.13-q14.1, and losses in 13q12.13-q12.3, and 18q21.32-q23. ALCL cell lines SR-786 and DEL, showed gains in cytobands 5p15.32-p14.3, 20p12.3-q13.11, and 20q13.2-q13.32. Both pairs of HL and ALCL cell lines showed losses in 18q21.32-18q23.

Conclusion

This study is considered to be the first one describing HL and ALCL cell line genomes at sub-megabase resolution. This high-resolution analysis allowed us to propose novel candidate target genes that could potentially contribute to the pathogenesis of HL and ALCL. FISH was used to confirm the amplification of all three isoforms of the trypsin gene (PRSS1/PRSS2/PRSS3) in KMH2 and L428 (HL) and DEL (ALCL) cell lines. These are novel findings that have not been previously reported in the lymphoma literature, and opens up an entirely new area of research that has not been previously associated with lymphoma biology. The findings raise interesting possibilities about the role of signaling pathways triggered by membrane associated serine proteases in HL and aggressive NHL, similar to those described in epithelial tumors.
Appendix
Available only for authorised users
Literature
1.
Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992, 68 (3): 421-427.CrossRefPubMed
2.
Vecchi V, Burnelli R, Pileri S, Rosito P, Sabattini E, Civino A, Pericoli R, Paolucci G: Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood. Med Pediatr Oncol. 1993, 21 (6): 402-410.CrossRefPubMed
3.
Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB: CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem. 1996, 271 (22): 12852-12858.CrossRefPubMed
4.
Kuppers R, Hansmann ML: The Hodgkin and Reed/Sternberg cell. Int J Biochem Cell Biol. 2005, 37 (3): 511-517.CrossRefPubMed
5.
Schwering I, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V, Hansmann ML, Dalla-Favera R, Rajewsky K, Kuppers R: Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003, 101 (4): 1505-1512.CrossRefPubMed
6.
Morris SW, Kirstein MN, Valentine MB, Dittmer K, Shapiro DN, Look AT, Saltman DL: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994, 263 (5151): 1281-1284.CrossRefPubMed
7.
Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG: Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia. 2000, 14 (9): 1533-1559.CrossRefPubMed
8.
Vanhentenrijk V, Vanden Bempt I, Dierickx D, Verhoef G, Wlodarska I, De Wolf-Peeters C: Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling. J Pathol. 2006, 210 (2): 155-162.CrossRefPubMed
9.
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994, 84 (5): 1361-1392.PubMed
10.
Jaffe ES, Krenacs L, Raffeld M: Classification of T-cell and NK-cell neoplasms based on the REAL classification. Ann Oncol. 1997, 8 (Suppl 2): 17-24.CrossRefPubMed
11.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999, 17 (12): 3835-3849.PubMed
12.
Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992, 258 (5083): 818-821.CrossRefPubMed
13.
14.
Wessendorf S, Schwaenen C, Kohlhammer H, Kienle D, Wrobel G, Barth TF, Nessling M, Moller P, Dohner H, Lichter P, Bentz M: Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization. Oncogene. 2003, 22 (9): 1425-1429.CrossRefPubMed
15.
Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, Cremer T, Lichter P: Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer. 1997, 20: 399-407.CrossRefPubMed
16.
Hui AB, Lo KW, Teo PM, To KF, Huang DP: Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol. 2002, 20 (3): 467-473.PubMed
17.
Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coe BP, Snijders A, Albertson DG, Pinkel D, Marra MA: A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet. 2004, 36 (3): 299-303.CrossRefPubMed
18.
Melendez B, Diaz-Uriarte R, Cuadros M, Martinez-Ramirez A, Fernandez-Piqueras J, Dopazo A, Cigudosa JC, Rivas C, Dopazo J, Martinez-Delgado B, Benitez J: Gene expression analysis of chromosomal regions with gain or loss of genetic material detected by comparative genomic hybridization. Genes Chromosomes Cancer. 2004, 41 (4): 353-365.CrossRefPubMed
19.
Joos S, Granzow M, Holtgreve-Grez H, Siebert R, Harder L, Martin-Subero JI, Wolf J, Adamowicz M, Barth TF, Lichter P, Jauch A: Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer. 2003, 103 (4): 489-495.CrossRefPubMed
20.
Gogusev J, Telvi L, Nezelof C: Molecular cytogenetic aberrations in CD30+ anaplastic large cell lymphoma cell lines. Cancer Genet Cytogenet. 2002, 138 (2): 95-101.CrossRefPubMed
21.
Yamaguchi M, Yamamoto K, Miura O: Aberrant expression of the LHX4 LIM-homeobox gene caused by t(1;14)(q25;q32) in chronic myelogenous leukemia in biphenotypic blast crisis. Genes Chromosomes Cancer. 2003, 38 (3): 269-273.CrossRefPubMed
22.
Malago W, Sommer CA, Del Cistia Andrade C, Soares-Costa A, Abrao Possik P, Cassago A, Santejo Silveira HC, Henrique-Silva F: Gene expression profile of human Down syndrome leukocytes. Croat Med J. 2005, 46 (4): 647-656.PubMed
23.
Glant TT, Kamath RV, Bardos T, Gal I, Szanto S, Murad YM, Sandy JD, Mort JS, Roughley PJ, Mikecz K: Cartilage-specific constitutive expression of TSG-6 protein (product of tumor necrosis factor alpha-stimulated gene 6) provides a chondroprotective, but not antiinflammatory, effect in antigen-induced arthritis. Arthritis Rheum. 2002, 46: 2207-2218.CrossRefPubMed
24.
Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D, Foidart JM: Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol. 2004, 57 (6): 577-584.PubMedCentralCrossRefPubMed
25.
26.
Khatri P, Sellamuthu S, Malhotra P, Amin K, Done A, Draghici S: Recent additions and improvements to the Onto-Tools. Nucleic Acids Res. 2005, W762-765. 33 Web Server
27.
28.
James L: Comparative genomic hybridization as a tool in tumour cytogenetics. J Pathol. 1999, 187: 385-395.CrossRefPubMed
29.
Joos S, Menz CK, Wrobel G, Siebert R, Gesk S, Ohl S, Mechtersheimer G, Trumper L, Moller P, Lichter P, Barth TF: Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002, 99 (2): 1381-1387.CrossRefPubMed
30.
Weber-Matthiesen K, Deerberg J, Poetsch M, Grote W, Schlegelberger B: Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease. Blood. 1995, 86 (4): 1464-1468.PubMed
31.
Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B, Grote W, Novo FJ, Calasanz MJ, Hansmann ML: Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 2002, 99 (4): 1474-1477.CrossRefPubMed
32.
Kluiver J, Kok K, Pfeil I, de Jong D, Blokzijl T, Harms G, van der Vlies P, Diepstra A, Atayar C, Poppema S: Golobal correlation of genome and transcriptome changes in classical Hodgkin lymphoma. Hematol Oncol. 2006, 25 (1): 21-29. 10.1002/hon.804.CrossRef
33.
Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T, Bellas C, Castano A, Diez A, Flores T: Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003, 101 (2): 681-689.CrossRefPubMed
34.
Sanchez-Aguilera A, Sanchez-Beato M, Garcia JF, Prieto I, Pollan M, Piris MA: p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood. 2002, 99 (4): 1411-1418.CrossRefPubMed
35.
Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001, 22 (2): 153-183.PubMed
36.
Gutkind JS: Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Sci STKE. 2000, 2000 (40): RE1-PubMed
37.
Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, Vauthey JN, Carbone A, Younes A: MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003, 102 (3): 1019-1027.CrossRefPubMed
38.
Engstrom K, Willen H, Kabjorn-Gustafsson C, Andersson C, Olsson M, Goransson M, Jarnum S, Olofsson A, Warnhammar E, Aman P: The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol. 2006, 168 (5): 1642-1653.PubMedCentralCrossRefPubMed
39.
Goransson M, Elias E, Stahlberg A, Olofsson A, Andersson C, Aman P: Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. Int J Cancer. 2005, 115 (4): 556-560.CrossRefPubMed
40.
41.
Shuai K: The STAT family of proteins in cytokine signaling. Prog Biophys Mol Biol. 1999, 71 (3–4): 405-422.CrossRefPubMed
42.
Holtick U, Vockerodt M, Pinkert D, Schoof N, Sturzenhofecker B, Kussebi N, Lauber K, Wesselborg S, Loffler D, Horn F: STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia. 2005, 19 (6): 936-944.CrossRefPubMed
43.
Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, Mak TW: Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002, 99 (2): 618-626.CrossRefPubMed
44.
45.
Bromberg J, Darnell JEJ: The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000, 19 (21): 2468-2473.CrossRefPubMed
46.
Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, A R: STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003, 197 (2): 157-168.CrossRefPubMed
47.
Cochet O, Frelin C, Peyron JF, Imbert V: Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal. 2006, 18 (4): 449-455.CrossRefPubMed
48.
Wang Y, Li G: ING3 promotes UV-induced apoptosis via Fas/caspase-8 pathway in melanoma cells. J Biol Chem. 2006, 281 (17): 11887-11893.CrossRefPubMed
49.
Watson SK, deLeeuw RJ, Ishkanian AS, Malloff CA, Lam WL: Methods for high throughput validation of amplified fragment pools of BAC DNA for constructing high resolution CGH arrays. BMC Genomics. 2004, 5 (1): 6-PubMedCentralCrossRefPubMed
50.
de Leeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, Dyer MJ, Staudt LM, Martinez-Climent JA, Lam WL: Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet. 2004, 13 (17): 1827-1837.CrossRefPubMed
51.
Wong KK, deLeeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, Horsman DE, MacAulay C, Ng RT, Brown CJ, Eichler EE, Lam WL: A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet. 2007, 80 (1): 91-104.PubMedCentralCrossRefPubMed
52.
53.
Brown LA, Huntsman D: Fluorescent in situ hybridization on tissue microarrays: challenges and solutions. J Mol Histol. 2007, 38 (2): 151-7.CrossRefPubMed
54.
Franke S, Wlodarska I, Maes B, Vandenberghe P, Delabie J, Hagemeijer A, De Wolf-Peeters C: Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. Blood. 2001, 97 (6): 1845-1853.CrossRefPubMed
55.
Falzetti D, Crescenzi B, Matteuci C, Falini B, Martelli MF, Van Den Berghe H, Mecucci C: Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease. Haematologica. 1999, 84 (4): 298-305.PubMed
Metadata
Title
Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines
Authors
Faisal M Fadlelmola
Minglong Zhou
Ronald J de Leeuw
Nirpjit S Dosanjh
Karynn Harmer
David Huntsman
Wan L Lam
Diponkar Banerjee
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2008
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-7-2

Other articles of this Issue 1/2008

Molecular Cancer 1/2008 Go to the issue

Research

The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer

Review

Evaluation of cell types for assessment of cytogenetic damage in arsenic exposed population

Research

Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile

Research

Metabolite profiling of human colon carcinoma – deregulation of TCA cycle and amino acid turnover

Research

Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK

Short communication

Intravenous administration of the conditionally replicative adenovirus Ad5-Δ24RGD induces regression of osteosarcoma lung metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits